Neurosense Therapeutics Ltd. (NRSN) has released an update.
NeuroSense Therapeutics Ltd., a biotech company focused on neurodegenerative diseases, has announced its return to compliance with NASDAQ’s minimum bid price rule, thanks to its shares maintaining a closing bid price of $1.00 or more for 10 consecutive days. The CEO expressed optimism about advancing their treatment, PrimeC, following successful Phase 2b trial results and the upcoming Phase 3 trials in the US. This milestone underscores the company’s commitment to meeting key regulatory standards and advancing their clinical programs.
For further insights into NRSN stock, check out TipRanks’ Stock Analysis page.
